More information: Takuya Nakagawa et al, Inhibition of human-HPV hybrid ecDNA enhancers reduces oncogene expression and tumor growth in oropharyngeal cancer, Nature Communications (2025). DOI: 10. ...

including cancer that affects the nose and throat. These are known as HPV-associated oropharyngeal cancers, and the incidence of these tumors is rising. While many of these cancers are treatable if ...

HPV-related throat cancers are rising, but risks can be lowered by avoiding tobacco, limiting alcohol, getting vaccinated, ...

A vaccine that blocks infection with the human papillomavirus has helped to lower cervical cancer rates. Researchers want to ...

Human papillomavirus (HPV), particularly the high-risk HPV16 subtype, is a major driver of certain cancers, including cervical, oropharyngeal, anal and penile cancers. The E6 and E7 proteins produced ...

The first national conference on HPV in Indy discussed advances like self-collected HPV testing for cancer prevention.

SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.

The incidence of Human Papillomavirus (HPV)-associated oropharyngeal cancers — tumors of the back of the mouth and throat — is rising. If caught early, most of these cancers have a high ...

HPV and human genes can combine to form extrachromosomal circular DNA (ecDNA) in oropharyngeal cancer cells, which enhances tumor-promoting gene expression and accelerates tumor growth.